Korsana Therapeutics launched with $175 million in venture backing from investors including Wellington, Sanofi Ventures and a J.P. Morgan affiliate to advance KRSA‑028, an anti‑amyloid antibody program spun out of Paragon Therapeutics. The company plans to push the asset toward clinical testing, targeting the crowded but still high‑value Alzheimer’s antibody market. Korsana will use the funds to prepare for a planned clinical start in 2027 and to develop the antibody’s translational package. The raise underscores continued investor appetite for anti‑amyloid approaches despite recent competition, and sets up Korsana to compete with established antibody developers pursuing disease‑modifying strategies for Alzheimer’s.